Dr. Suraj Samtani

🧬 OptiTROP-Lung04 | Phase III 💥 A TROP2-ADC breakthrough after EGFR-TKI failure! 💊 Sacituzumab Tirumotecan (sac-TMT) vs 💉 Platinum-chemo 📍 EGFR-mutated NSCLC (n = 376 | 95 % prior 3G TKI) 📊 Key Results ⚡ PFS: 8.3 mo vs 4.3 mo (HR 0.49 [0.39–0.62], p < 0.0001) 💪 OS: NR vs 17.4 mo (HR 0.60 [0.44–0.82], p = 0.0006) 🎯 ORR: 60.6 % vs 43.1 % ⏱️ DoR: 8.3 mo vs 4.2 mo ⚕️ Grade ≥ 3 AEs: 49.5 % vs 52.2 % 🚫 No ILD or pneumonitis reported 💡 Takeaway: sac-TMT delivered double PFS + OS benefit with a tolerable profile — may become the next-line standard after EGFR-TKIs in EGFRm NSCLC. 📖 LBA5 – Zhang et al., ESMO 2025 (Proffered Paper) #ESMO25 #OncoTwitter #LungCancer #NSCLC #EGFR #TROP2 @OncoAlert @esmo_open

#ESMO25 Pegfilgrastim timing matters! In this randomized phase III trial (n=159, early-stage BC): Giving pegfilgrastim 72h after chemo — instead of 24–48h — cut bone pain by >50% without increasing neutropenia or FN risk.

“Glad to share our work on the importance of exercise in cancer care at our centre with Chilean 🇨🇱 patients.” doi.org/10.1200/OP.202… @ASCO #ASCOQLTY25 @JCO_ASCO

Dont miss our abstract presented at #ASCOQLTY25 about the importance of Exercise and Cancer in Chilean 🇨🇱 Patients @ASCO @JCO_ASCO @ministeriosalud

@StephenVLiu @IASLC Amazing!!! 👏👏👏

Join us in downtown Washington, DC on Saturday October 4th for the DC Lung Cancer Conference, an @IASLC endorsed, 1-day CME meeting covering updates in lung cancer, featuring 58 thoughtful & dynamic faculty members. #DCLung25 Register today at medstarhealth.org/dclung25

@n8pennell Congrats!!!!!

After 17 years at the Cleveland Clinic, I’m starting today as Senior Vice President and Worldwide Head of Hematology Oncology Medical Affairs at Bristol-Myers Squibb. I’m deeply grateful to my colleagues and patients at the Clinic for my experiences there. In my new role, I aim to help bring life-changing drugs to more people affected by cancer worldwide.

Agradecido de compartir esta entrevista: “El principal desafío en Chile no está únicamente en el acceso a tratamientos innovadores, sino en los tiempos de diagnóstico del cáncer” noticias.uft.cl/dr-suraj-samta… @Emol @CLICaP_ @ministeriosalud @ASCO @myESMO

Les comparto esta noticia @24HorasTVN amp.24horas.cl/conciencia-24-…

Amazing

Glad to share our article about Clinical and economic impact of the availability of innovative therapies for NSCLC patients in Latam sciencedirect.com/science/articl… Great Latin America effort led by @AndresFCardonaZ @ogarrieta @LuciaViola9 @LuisRaezMD @TheLancetOncol @LancetGH

[Audio] Oncólogo chileno destacó en premiación como líder mundial en la lucha contra el cáncer #Cooperativa90 tinyurl.com/yo7qkb4k

This paper shows that substantial clinical and economic impact of delays in approving innovative therapies, underscoring the potential of improving regulatory processes to increase the availability of #lungcancer treatments. Congrats to @AndresFCardonaZ @ogarrieta for leading this effort and thanks for inviting us to participate! @LuciaViola9 @DrClaudiomartin @IASLC #LCSM @TheLancet @TheLancetOncol @thelancet @MCIStrong @mhshospital thelancet.com/journals/lanam…

Hoy en @lun 🎗️ 🎗️ 🎗️

Oncólogo chileno es reconocido entre los 40 líderes mundiales en la lucha contra el cáncer cooperativaciencia.cl/salud/2025/06/…

@MtnStateDoc It was a pleasure meeting you @MtnStateDoc ! Future looks bright with you in the field!

#ASCO25- Humbled and motivated by so many thought leaders and brilliant minds in the field of Hematology/Oncology! Grateful for the insights and innovations shared and excited to bring new knowledge back to practice! Thank you for the mentorship, Dr. @SamtaniSuraj !

Truly honoured and grateful for being recognized as one of “40 under 40 in cancer” by @avbcancercare with such outstanding oncologists @oncology_bg @lungoncdoc My deepest thanks to my family, mentors colleagues and cancer community for their support and inspiration #ASCO25

Truly honoured and grateful for being recognized as Emerging Leaders “40 under 40 in cancer” by @avbcancercare My deepest thanks to my family, mentors colleagues and cancer community for their support and inspiration Looking forward to celebrate in Chicago #ASCO #ASCO25

Truly honoured and grateful for being recognized as Rising Star and Emerging Leaders “40 under 40 in cancer” by @avbcancercare My deepest thanks to my family, mentors colleagues and cancer community for their support and inspiration Looking forward to celebrating Chicago.